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Conclusion: Core biopsy with a biopsy gun increase the diagnostic 
accuracy with a higher histologic predictive rate and no obvious ad-
ditional risk of complications.
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Background: In lung cancer, stage has classically been the most 
important prognostic factor for disease progression and survival. How-
ever, stage may be simply a surrogate for underlying tumor burden. The 
purpose of this study was to assess the prognostic value of pre-treat-
ment tumor volume as measured by FDG-PET imaging.
Methods: We identiﬁed a cohort of 19 patients with lung cancer who 
had staging PET-CT scans prior to any therapy, and adequate follow-
up. Follow-up was complete to the time of progression for 18 of 19 
patients, and to the time of death for 15 of 19 patients. Four patients 
remain alive. We used custom software to segment metabolically active 
tumor regions semi-automatically on PET scans. We determined the 
relationship between time to progression (TTP) and two PET param-
eters: total metabolic tumor volume (MTV), and standardized uptake 
value (SUV).
Results: The median TTP for the cohort was 8.6 months (range 0.7-
25). The median overall survival (OS) was 15 months. The median 
MTV was 27 mL. On multivariate Cox proportional hazards regression 
analysis, an increase in MTV of 25 mL (the difference between the 75th 
and 25thpercentiles) was associated with a 2.6 fold increase in hazard 
of progression, statistically signiﬁcant (p=0.023) after controlling 
for stage, age, KPS, and weight loss. Figure 1 shows the relationship 
between MTV and progression-free survival. Similarly, an increase in 
MTV of 25 mL was associated with a 2.9 fold increase in the hazard 
of death (p=0.0017). We did not ﬁnd a signiﬁcant relationship between 
SUV and TTP or OS.
Conclusions: In this study, high tumor burden assessed by PET MTV 
is a poor prognostic feature in lung cancer independent of stage, age, 
KPS, and weight loss. This may be promising for stratifying patients in 
randomized trials, and ultimately for selecting risk-adapted therapies. 
These results will need to be validated in larger cohorts with longer fol-
low-up, as well as evaluated prospectively.
Figure 1
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Usefulness of fluorodeoxyglucose positron emission tomography 
integrated with computed tomography (FDG-PET/CT) in 
determining the resectability of primary lung cancer
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Background: The integration of computed tomography (CT) and 
FDG-PET provides better speciﬁcity and sensitivity in tumor imaging 
than either component alone. We prospectively evaluated FDG-PET/
CT as a method for determining surgical indications in patients with 
primary lung cancer. 
Methods: Consecutive patients with a diagnosis of primary lung cancer 
based on preoperative cytology or histologic examination in our hospi-
tal were enrolled prospectively. Conventional disease staging was per-
formed using chest CT, abdominal CT, brain magnetic resonance imag-
ing (MRI), and bone scintigraphy. Treatment strategy was determined 
based on conventional staging. Independently, simultaneous PET-stag-
ing was performed based on whole body FDG-PET/CT and brain MRI. 
Results of preoperative PET were compared with surgical specimens of 
hilar and mediastinal lymph nodes. In nonsurgical cases, node (N) and 
metastasis (M) factors diagnosed by PET were evaluated based on the 
clinical course or results from biopsy specimens of speciﬁc sites. 
Results: Twenty men and 22 women, age range, 47 to 87 years (71±10, 
mean±SD), were enrolled. Histology included 27 adenocarcinomas, 10 
squamous cell carcinomas, and 5 small cell carcinomas. Clinical stage 
by conventional staging was c-stages IA or B in 13, IIA or B in 3, IIIA 
in 6, IIIB in 7, and IV in 13. According to the conventional staging, 
16 patients underwent surgery. By PET-staging, 9 cases (21%) were 
